Microemulsions for oral administration and their therapeutic applications

Expert Opinion on Drug Delivery

Volumn 9, Issue 8, 2012, Pages 937-951

  Gibaud, Stéphane ^a,b   Attivi, David ^b  

^a UNIVERSITÉ DE LORRAINE   (France)

^b Centre Hospitalier de Neufchâteau   (France)

Author keywords

Bioavailability; Microemulsion; Nanoemulsion; Self emulsifying system

Indexed keywords

CREMOPHOR; CYCLOSPORIN A; DIETHYLENE GLYCOL MONOETHYL ETHER; DOCETAXEL; GELUCIRE; GLYCEROL MONOLINOLEATE; GLYCEROL OLEATE; GLYCERYL MONOLINOLEATE; IBUPROFEN; LABRASOL; LEUPRORELIN; LINOLEIC ACID; NIFEDIPINE; OCTANOIC ACID; OIL; OLEOYL POLYOXYL 6 GLYCERIDE; PIROXICAM; POLYSORBATE 20; POLYSORBATE 80; PROPYLENE GLYCOL CAPRYLATE; RAMIPRIL; RITONAVIR; SAQUINAVIR; SOLUTOL HS 15; SORBITANE MONOOLEATE; SURFACTANT; TRIGLYCEROL DIISOSTEARATE; TRIOCTANOIN; TRITON X 100; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AREA UNDER THE CURVE; CONDUCTANCE; DROPLET SIZE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG DELIVERY SYSTEM; DRUG SCREENING; DRUG SOLUBILITY; DRUG STABILITY; EVERTED SAC; EXPERIMENTAL RAT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; INTERMETHOD COMPARISON; INTESTINE ABSORPTION; INTESTINE PERFUSION; MAXIMUM PLASMA CONCENTRATION; MEMBRANE PERMEABILITY; MICROEMULSION; NEPHROTOXICITY; NONHUMAN; PARALLEL ARTIFICIAL MEMBRANE PERMEABILITY ASSAY; PHYSICAL CHEMISTRY; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; SELF MICROEMULSIFYING DRUG DELIVERY SYSTEM; TRANSPARENCY; USSING CHAMBER; VISCOSITY; ZETA POTENTIAL;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CACO-2 CELLS; CHEMISTRY, PHARMACEUTICAL; DRUG DELIVERY SYSTEMS; EMULSIONS; HIV INFECTIONS; HUMANS; INTESTINAL ABSORPTION; OILS; SOLUBILITY; SURFACE-ACTIVE AGENTS;

EID: 84864240790     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2012.694865     Document Type: Review

References (119)

1. Hoar TP, Schulman JH. Transparent water-in-oil dispersions: The oleopathic hydro-micelle. Nature 1943;152:102-3
2. Schulman J, Stoeckenius W. Mechanism of formation and structure of micro emulsions by electron microscopy. J Phys Chem 1959;63:1677-80
3. Danielsson I, Lindman B. The definition of microemulsion. Colloids Surf 1981;3:391-2
4. Spernath A, Aserin A. Microemulsions as carriers for drugs and nutraceuticals. Adv Colloid Interface Sci 2006;128-130:47-64
5. Shafiq S, Shakeel F, Talegaonkar S, et al. Design and development of oral oil in water ramipril nanoemulsion formulation: In vitro and in vivo assessment. J Biomed Nanotechnol 2007;3:28-44
6. Muellertz A, Ogbonna A, Ren S, et al. New perspectives on lipid and surfactant based drug delivery systems for oral delivery of poorly soluble drugs. J Pharm Pharmacol 2010;62:1622-36
7. Noh GJ, Lee E-H, Lee SH, et al. Physicochemical properties, pharmacokinetics, and pharmacodynamics of a reformulated microemulsion propofol in rats. Anesthesiology 2008;109:436-47
8. Paolino D, Ventura C, Nistico S, et al. Lecithin microemulsions for the topical administration of ketoprofen: Percutaneous adsorption through human skin and in vivo human skin tolerability. Int J Pharm 2002;244:21-31
9. Date AA, Nagarsenker MS. Design and evaluation of self-nanoemulsifying drug delivery systems (SNEDDS) for cefpodoxime proxetil. Int J Pharm 2007;329:166-72
10. Pouton CW. Formulation of poorly water-soluble drugs for oral administration: Physicochemical and physiological issues and the lipid formulation classification system. Eur J Pharm Sci 2006;29:278-87
11. Pouton CW. Lipid formulations for oral administration of drugs: Non-emulsifying, self-emulsifying and 'self-microemulsifying' drug delivery systems. Eur J Pharm Sci 2000;11(Suppl 2):S93-8
12. Gelderblom H, Verweij J, Nooter K, et al. Cremophor EL: The drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 2001;37:1590-8
13. Riehm H, Biedler JL. Potentiation of drug effect by Tween 80 in Chinese hamster cells resistant to actinomycin D and daunomycin. Cancer Res 1972;32:1195-200
14. Coon JS, Knudson W, Clodfelter K, et al. Solutol HS 15, nontoxic polyoxyethylene esters of 12-hydroxystearic acid, reverses multidrug resistance. Cancer Res 1991;51:897-902
15. Zordan-Nudo T, Ling V, Liu Z, et al. Effects of nonionic detergents on P-glycoprotein drug binding and reversal of multidrug resistance. Cancer Res 1993;53:5994-6000
16. Charman SA, Charman WN, Rogge MC, et al. Self-emulsifying drug delivery systems: Formulation and biopharmaceutic evaluation of an investigational lipophilic compound. Pharm Res 1992;9:87-93
17. Shah N, Carvajal M, Patel C, et al. Self-emulsifying drug-delivery systems (SEDDS) with polyglycolyzed glycerides for improving in-vitro dissolution and oral absorption of lipophilic drugs. Int J Pharm 1994;106:15-23
18. Porter CJH, Charman WN. Uptake of drugs into the intestinal lymphatics after oral administration. Adv Drug Deliv Rev 1997;25:71-89
19. Grove M, Mullertz A, Nielsen J, et al. Bioavailability of seocalcitol II: Development and characterisation of self-microemulsifying drug delivery systems (SMEDDS) for oral administration containing medium and long chain triglycerides. Eur J Pharm Sci 2006;28:233-42
20. Schulman JH, Montagne JB. Formation of microemulsions by aminoalkyl alcohols. Ann N Y Acad Sci 1961;92:366-71
21. Aboofazeli R, Patel N, Thomas M, et al. Investigations into the formation and characterization of phospholipid microemulsions. IV. Pseudo-ternary phase-diagrams of systems containing water-lecithin-alcohol and oil-the influence of oil. Int J Pharm 1995;125:107-16
22. Attivi D, Ajana I, Astier A, et al. Development of microemulsion of mitotane for improvement of oral bioavailability. Drug Dev Ind Pharm 2010;36:421-7
23. Shafiq S, Shakeel F, Talegaonkar S, et al. Development and bioavailability assessment of ramipril nanoemulsion formulation. Eur J Pharm Biopharm 2007;66:227-43
24. Kang B, Lee J, Chon S, et al. Development of self-microemulsifying drug delivery systems (SMEDDS) for oral bioavailability enhancement of simvastatin in beagle dogs. Int J Pharm 2004;274:65-73
25. Lu J-L, Wang J-C, Zhao S-X, et al. Self-microemulsifying drug delivery system (SMEDDS) improves anticancer effect of oral 9-nitrocamptothecin on human cancer xenografts in nude mice. Eur J Pharm Biopharm 2008;69:899-907
26. Osipow LI. Transparent emulsions. J Soc Cosmet Chem 1963;14:277-85
27. He L, Wang G-L, Zhang Q. An alternative paclitaxel microemulsion formulation: Hypersensitivity evaluation and pharmacokinetic profile. Int J Pharm 2003;250:45-50
28. Patil P, Patil V, Paradkar A. Formulation of a self-emulsifying system for oral delivery of simvastatin: In vitro and in vivo evaluation. Acta Pharm 2007;57:111-22
29. Prince LM. A theory of aqueous emulsions. I. Negative interfacial tension at the oil/water interface. J Colloid Interface Sci 1967;23:165-73
30. Weiss J. Static and dynamic interfacial tension analysis. In: Wrolstad RE, Decker EA, Schwartz SJ, et al. editors. Handbook of food analytical chemistry, water, proteins, enzymes, lipids, and carbohydrates. Wiley-Interscience; Hoboken, New Jersey: 2005. p. 631-46
31. Lim H, Lee S, Mo D, et al. Effect of cosurfactant on microemulsion phase behavior in NP7 surfactant system. J Korean Ind Eng Chem 2011;22:416-22
32. Bellocq AM, Bourbon D, Lemanceau B, et al. Thermodynamic, interfacial, and structural properties of polyphasic microemulsion systems. J Colloid Interface Sci 1982;89:427-40
33. Chen LH, Zhao XT, Wu DZ, et al. Screening the prescription microemulsion by conductivity and the phase behavior. Chin Pharm J 2011;46:40-3
34. Brime B, Frutos P, Bringas P, et al. Comparative pharmacokinetics and safety of a novel lyophilized amphotericin B lecithin-based oil-water microemulsion and amphotericin B deoxycholate in animal models. J Antimicrob Chemother 2003;52:103-9
35. Gershanik T, Benzeno S, Benita S. Interaction of a self-emulsifying lipid drug delivery system with the everted rat intestinal mucosa as a function of droplet size and surface charge. Pharm Res 1998;15:863-9
36. Yang S, Gursoy R, Lambert G, et al. Enhanced oral absorption of paclitaxel in a novel self-microemulsifying drug delivery system with or without concomitant use of P-glycoprotein inhibitors. Pharm Res 2004;21:261-70
37. Mandal S. Microemulsion drug delivery system: Design and development for oral bioavailability enhancement of lovastatin. S Afr Pharm J 2011;78:44-50
38. Patel V, Kukadiya H, Mashru R, et al. Development of microemulsion for solubility enhancement of clopidogrel. Iran J Pharm Res 2010;9:327-34
39. Pal R. Techniques for measuring the composition (Oil and Water-Content) of emulsions - a State-of-the-art review. Colloid Surf A 1994;84:141-93
40. Araya H, Tomita M, Hayashi M. The novel formulation design of self-emulsifying drug delivery systems (SEDDS) type O/W microemulsion III: The permeation mechanism of a poorly water soluble drug entrapped O/W microemulsion in rat isolated intestinal membrane by the Ussing chamber method. Drug Metab Pharmacokinet 2006;21:45-53
41. Malenkov AG, Bogatyreva SA, Bozhkova VP, et al. Reversible alterations of the surface of ascites tumour cells induced by a surface-active substance, Tween 60. Exp Cell Res 1967;48:307-18
42. Yin Y-M, Cui F-D, Mu C-F, et al. Docetaxel microemulsion for enhanced oral bioavailability: Preparation and in vitro and in vivo evaluation. J Control Release 2009;140:86-94
43. Brossard D, Crauste-Manciet S, Saleh M, et al. Methods for making a formulation and use thereof for administering polar drugs. WO2010067035A1; 2010
44. Han D-H, Jin Z-H, Jin Y-Z, et al. Thermal reversible microemulsion system for poorly water-soluble YH439 for oral delivery. Chem Pharm Bull 2010;58:11-15
45. Karasulu H. Microemulsions as novel drug carriers: The formation, stability, applications and toxicity. Exp Opin Drug Deliv 2008;5:119-35
46. Sha X, Yan G, Wu Y, et al. Effect of self-microemulsifying drug delivery systems containing Labrasol on tight junctions in Caco-2 cells. Eur J Pharm Sci 2005;24:477-86
47. Masungi C, Mensch J, Van Dijck A, et al. Parallel artificial membrane permeability assay (PAMPA) combined with a 10-day multiscreen Caco-2 cell culture as a tool for assessing new drug candidates. Pharmazie 2008;63:194-9
48. Kansy M, Senner F, Gubernator K. Physicochemical high throughput screening: Parallel artificial membrane permeation assay in the description of passive absorption processes. J Med Chem 1998; 41:1007-10
49. Chen X, Murawski A, Patel K, et al. A novel design of artificial membrane for improving the PAMPA model. Pharm Res 2008;25:1511-20
50. Kahan BD. Cyclosporine. N Engl J Med 1989;321:1725-1738
51. Beveridge T, Gratwohl A, Michot F, et al. Cyclosporin A: Pharmacokinetics after a single dose in man and serum levels after multiple dosing in recipients of allogeneic bone-marrow grafts. Curr Ther Res 1981;30:5-18
52. Frey FJ, Horber FF, Frey BM. Trough levels and concentration time curves of cyclosporine in patients undergoing renal transplantation. Clin Pharmacol Ther 1988;43:55-62
53. Ptachcinski RJ, Venkataramanan R, Burckart GJ. Clinical pharmacokinetics of cyclosporin. Clin Pharmacokinet 1986;11:107
54. Mehta MU, Venkataramanan R, Burckart GJ, et al. Effect of bile on cyclosporin absorption in liver transplant patients. Br J Clin Pharmacol 1988;25:579-84
55. Venkataramanan R, Burckhart GJ, Ptachcinski RJ. Pharmacokinetics and monitoring of cyclosporine following orthotopic liver transplantation. Semin Liver Dis 1985;5:357-68
56. Trull AK, Tan KKC, Tan L, et al. Absorption of cyclosporin from conventional and new microemulsion oral formulations in liver transplant recipients with external biliary diversion. Br J Clin Pharmacol 1995;39:627-31
57. Kovarik JM, Mueller EA, Van Bree JB, et al. Reduced inter- and intraindividual variability in cyclosporine pharmacokinetics from a microemulsion formulation. J Pharm Sci 1994;83:444-6
58. Trull AK, Tan KK, Uttridge J, et al. Cyclosporin absorption from microemulsion formulation in liver transplant recipient. Lancet 1993;341:433
59. Grevel J, Nesch E, Abisch E, et al. Pharmacokinetics of oral cyclosporin a (Sandimmun) in healthy subjects. Eur J Clin Pharmacol 1986;31:211-16
60. Drewe J, Meier R, Vonderscher J, et al. Enhancement of the oral absorption of cyclosporin in man. Br J Clin Pharmacol 1992;34:60-4
61. Kovarik JM, Mueller EA, Van Bree JB, et al. Within-day consistency in cyclosporine pharmacokinetics from a microemulsion formulation in renal transplant patients. Ther Drug Monit 1994;16:232-7
62. Mueller EA, Kovarik JM, Van Bree JB, et al. Improved dose linearity of cyclosporine pharmacokinetics from a microemulsion formulation. Pharm Res 1994;11:301-4
63. Griffin BT, O'Driscoll CM. A comparison of intestinal lymphatic transport and systemic bioavailability of saquinavir from three lipid-based formulations in the anaesthetised rat model. J Pharm Pharmacol 2006;58:917-25
64. Allard JP, Aghdassi E, Chau J, et al. Effects of vitamin E and C supplementation on oxidative stress and viral load in HIV-infected subjects. Aids 1998;12:1653
65. Surjyanarayan M, Snigdha S M, Naazneen S, et al. Design and development of Saquinavir microemulsion for the oral bioavailability enhancement. Int J Pharm Tech Res 2009;1:1442-8
66. Hugen PWH, Burger DM, Koopmans PP, et al. Saquinavir soft-gel capsules (Fortovase) give lower exposure than expected, even after a high-fat breakfast. Pharm World Sci 2002;24:83-6
67. Fatouros DG, Karpf DM, Nielsen FS, et al. Clinical studies with oral lipid based formulations of poorly soluble compounds. Ther Clin Risk Manage 2007;3:591-604
68. Goddeeris C, Coacci J, Van den Mooter G. Correlation between digestion of the lipid phase of SMEDDS and release of the anti-HIV drug UC 781 and the anti-mycotic drug enilconazole from SMEDDS. Eur J Pharm Biopharm 2007;66:173-81
69. Ghosh PK, Majithiya RJ, Umrethia ML, et al. Design and development of microemulsion drug delivery system of acyclovir for improvement of oral bioavailability. AAPS PharmSciTech 2006;7:E1-6
70. Chouksey R, Pandey H, Jain AK, et al. Preparation and evaluation of the self emulsifying drug delivery system containing atorvastatin HMG-CoA inhibiter. Int J Pharm Pharm Sci 2011;3:147-52
71. Agueros M, Ruiz-Gaton L, Vauthier C, et al. Combined hydroxypropyl-beta- cyclodextrin and poly(anhydride) nanoparticles improve the oral permeability of paclitaxel. Eur J Pharm Sci 2009;38:405-13
72. Sharma U, Balasubramanian S, Straubinger R. Pharmaceutical and physical properties of paclitaxel (Taxol) complexes with cyclodextrins. J Pharm Sci 1995;84:1223-30
73. Perez EA. Novel enhanced delivery taxanes: An update. Semin Oncol 2007;34:S1-5
74. King KM, Lupichuk S, Baig L, et al. Optimal use of taxanes in metastatic breast cancer. Journal 2009;16:8-20
75. Michaud LB, Valero V, Hortobagyi G. Risks and benefits of taxanes in breast and ovarian cancer. Drug Saf 2000;23:401
76. Fanucchi M, Khuri FR. Taxanes in the treatment of non-small cell lung cancer. Treat Res Med 2006;5:181-91
77. Schrijvers D, Vermorken JB. Taxanes in head and neck cancer. Future Oncol 2005;1:829-39
78. Kratz F. Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles. J Control Release 2008;132:171-83
79. Khandavilli S, Panchagnula R. Nanoemulsions as versatile formulations for paclitaxel delivery: Peroral and dermal delivery studies in rats. J Investig Dermatol 2007;127:154-62
80. Nichols J, Richardson A. Effects of DDD on steroid response and blood flow through the adrenal after ACTH. Proc Soc Exp Biol Med 1960;104:539-42
81. Wallace E, Silverstein J, Villadolid L, et al. Cushing's syndrome due to adrenocortical hyperplasia. Treatment with an inhibitor of adrenocortical secretions. N Engl J Med 1961;265:1088-93
82. Attivi D, Gibaud S. Place du mitotane dans la prise en charge du carcinome corticosurrenalien. Act Pharm Hosp 2011;7:39-41
83. Batung F, Chajmowics M. Self-microemulsifying mitotane composition. WO20101136952; 2010
84. Santos-Magalhaes NS, Pontes A, Pereira VM, et al. Colloidal carriers for benzathine penicillin G: Nanoemulsions and nanocapsules. Int J Pharm 2000;208:71-80
85. Heo M, Piao Z, Kim T, et al. Effect of solubilizing and microemulsifying excipients in polyethylene glycol 6000 solid dispersion on enhanced dissolution and bioavailability of ketoconazole. Arch Pharm Res 2005;28:604-11
86. Gui S-Y, Wu L, Peng DY, et al. Preparation and evaluation of a microemulsion for oral delivery of berberine. Pharmazie 2008;63:516-19
87. Chen B, Chow M. Focus on carvedilol: A novel beta-adrenergic blocking agent for the treatment of congestive heart failure. Formulary 1997;32:795-805
88. Morgan T. Clinical pharmacokinetics and pharmacodynamics of carvedilol. Clin Pharmacokinet 1994;26:335-46
89. Neugebauer G, Akpan W, von Mollendorff E, et al. Pharmacokinetics and disposition of carvedilol in humans. J Cardiovasc Pharmacol 1987;10(Suppl 11):S85-8
90. Wei L, Sun P, Nie S, et al. Preparation and evaluation of SEDDS and SMEDDS containing carvedilol. Drug Dev Ind Pharm 2005;31:785-94
91. Chinsangaram J, Honeychurch KM, Tyavanagimatt SR, et al. Pharmacokinetic comparison of a single oral dose of polymorph form I versus form V capsules of the anti-orthopoxvirus compound ST-246(R) in human volunteers. Antimicrob Agents Chemother 2012. [Epub ahead of print]
92. Yong CS, Lee M-K, Park Y-J, et al. Enhanced oral bioavailability of ibuprofen in rats by poloxamer gel using poloxamer 188 and menthol. Drug Dev Ind Pharm 2005;31:615-22
93. Saffoon N, Uddin R, Huda NH, et al. Enhancement of oral bioavailability and solid dispersion: A review. J Appl Pharm Sci 2011;1:13-20
94. Leuner C, Dressman J. Improving drug solubility for oral delivery using solid dispersions. Eur J Pharm Biopharm 2000;50:47-60
95. Ensign LM, Cone R, Hanes J. Oral drug delivery with polymeric nanoparticles: The gastrointestinal mucus barriers. Adv Drug Deliv Rev 2012;64:557-70
96. Florence AT. Issues in oral nanoparticle drug carrier uptake and targeting. J Drug Target 2004;12:65-70
97. Wong S, Kellaway I, Murdan S. Enhancement of the dissolution rate and oral absorption of a poorly water soluble drug by formation of surfactant-containing microparticles. Int J Pharm 2006;317:61-8
98. Muller R, Jacobs C, Kayser O. Nanosuspensions as particulate drug formulations in therapy: Rationale for development and what we can expect for the future. Adv Drug Deliv Rev 2001;47:3-19
99. Kanwar JR, Long BM, Kanwar RK. The use of cyclodextrins nanoparticles for oral delivery. Curr Med Chem 2011;18:2079-85
100. Ning X, Sun J, Han X, et al. Strategies to improve dissolution and oral absorption of glimepiride tablets: Solid dispersion versus micronization techniques. Drug Dev Ind Pharm 2011;37:727-36
101. Dai J, Nagai T, Wang X, et al. pH-sensitive nanoparticles for improving the oral bioavailability of cyclosporine A. Int J Pharm 2004;280:229-40
102. Wang X, Dai J, Chen Z, et al. Bioavailability and pharmacokinetics of cyclosporine A-loaded pH-sensitive nanoparticles for oral administration. J Control Release 2004;97:421-9
103. Italia J, Bhatt D, Bhardwaj V, et al. PLGA nanoparticles for oral delivery of cyclosporine: Nephrotoxicity and pharmacokinetic studies in comparison to Sandimmun Neoral-.. J Control Release 2007;119:197-206
104. El-Shabouri M. Positively charged nanoparticles for improving the oral bioavailability of cyclosporin-A. Int J Pharm 2002;249:101-8
105. Muller RH, Runge S, Ravelli V, et al. Oral bioavailability of cyclosporine: Solid lipid nanoparticles (SLN) versus drug nanocrystals. Int J Pharm 2006;317:82-9
106. Lai J, Lu Y, Yin Z, et al. Pharmacokinetics and enhanced oral bioavailability in beagle dogs of cyclosporine A encapsulated in glyceryl monooleate/poloxamer 407 cubic nanoparticles. Int J Nanomed 2010;5:13-23
107. Ankola DD, Battisti A, Solaro R, et al. Nanoparticles made of multi-block copolymer of lactic acid and ethylene glycol containing periodic side-chain carboxyl groups for oral delivery of cyclosporine A. J R Soc Interface 2010;7(Suppl 4):S475-81
108. Aliabadi HM, Brocks DR, Lavasanifar A. Polymeric micelles for the solubilization and delivery of cyclosporine A: Pharmacokinetics and biodistribution. Biomaterials 2005;26:7251-9
109. Guo J, Wu T, Ping Q, et al. Solubilization and pharmacokinetic behaviors of sodium cholate/lecithinmixed micelles containing cyclosporine A. Drug Deliv 2005;12:35-9
110. Lee E, Lee S, Choi H, et al. Bioavailability of cyclosporin A dispersed in sodium lauryl sulfate-dextrin based solid microspheres. Int J Pharm 2001;218:125-31
111. Guo J, Ping Q, Chen Y. Pharmacokinetic behavior of cyclosporin A in rabbits by oral administration of lecithin vesicle and Sandimmun Neoral. Int J Pharm 2001;216:17-21
112. Shah NM, Parikh J, Namdeo A, et al. Preparation, characterization and in vivo studies of proliposomes containing Cyclosporine A. J Nanosci Nanotechnol 2006;6:2967-73
113. Liu C, Wu J, Shi B, et al. Enhancing the bioavailability of cyclosporine a using solid dispersion containing polyoxyethylene (40) stearate. Drug Dev Ind Pharm 2006;32:115-23
114. Chen M, Wang J, Tzen J. Elevating Bioavailability of cyclosporine A via encapsulation in artificial oil bodies stabilized by caleosin. Biotech Prog 2005;21:1297-301
115. Hu L, Yang J, Liu W, et al. Preparation and evaluation of ibuprofen-loaded microemulsion for improvement of oral bioavailability. Drug Deliv 2011;18:90-5
116. Nazar MF, Khan AM, Shah SS. Microemulsion system with improved loading of piroxicam: A study of microstructure. AAPS PharmSciTech 2009;10:1286-94
117. Zheng JY, Fulu M-Y. Decrease of genital organ weights and plasma testosterone levels in rats following oral administration of leuprolide microemulsion. Int J Pharm 2006;307:209-15
118. Gupta A. Design and development of microemulsion drug delivery system of nifedipine for improvement of oral bioavailability. Res J Pharm Sci Biotech 2011;1:51-6
119. O'Driscoll CM. Lipid-based formulations for intestinal lymphatic delivery. Eur J Pharm Sci 2002;15:405-15